Enter your search term above.

Funding opportunities

In keeping with our mission, the LCRF grant program provides funding for research into the prevention, diagnosis, treatment and cure of lung cancer. Our funding mechanisms are designed to fund innovative projects across a variety of diverse topics and to support the careers of talented scientists. To learn about research that has been previously funded by LCRF, please visit the Our Investigators section. Information for investigators seeking funding for research, including an overview of our funding mechanisms and any current requests for proposals, can be found below. For questions about our grants, please contact us at grants@LCRF.org.

NOTE: The deadline for the LCRF-ALK Positive Research Grant has been extended to June 1, 2022; the deadline for the LCRF Minority Career Development Award (CDA) for Lung Cancer has been extended to June 3, 2022.


About Our Grants

LCRF Pilot Grant Program

The LCRF pilot grant program funds innovative projects across the full spectrum of basic, translational, clinical, epidemiological, health services, early detection, disparities, and social determinants of health research, focused on one or more of the following topics:

  • Lung cancer biology
  • Prevention and screening for early detection
  • Identification of new biomarkers
  • Development of more effective and less toxic therapies including but not limited to targeted and immune-therapies
  • Genetic and gene-environment interactions
  • Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes
  • Mechanisms of sensitivity and resistance to lung cancer therapies
  • Bioengineering approaches to understanding and/or treating lung cancer (i.e., theranostics, biomaterials, nanotechnology, controlled-drug release, and gene-therapy)
  • Supportive measures for people with lung cancer and their families

These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.

Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2022.


LCRF Research Grants on Oncogenic Drivers in Lung Cancer

LCRF has launched a new funding mechanism to support research projects with a focus on characterizing, identifying, treating or overcoming/preventing resistance to therapies in tumors harboring alterations in oncogenic drivers in NSCLC cells, tissues, mouse models, or patients. Work supported through this mechanism will addresses important mechanistic questions and developmental therapeutics across the care continuum and have the potential to increase survivorship. In 2022, in partnership with leading patient advocacy organizations, this grant mechanism will focus on three specific oncogenes: EGFR, MET and KRAS.

We encourage applications on a wide variety of topics related to EGFR, MET or KRAS-driven lung cancer, including, but not limited to the following:

  • Biology and mechanisms of tumor progression
  • Mechanisms of resistance to targeted therapies
  • Novel treatment approaches, combinations, and new therapies
  • Studies on the immune landscape, tumor microenvironment, and immunotherapies

These awards provide a maximum of $150,000 in funding over a period of two years to investigators with any level of research experience. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.

Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2022.

Additional specific topics of interest related to the individual oncogenic drivers are listed below.

LCRF and EGFR Resisters Research Grant on EGFR-Driven Lung Cancer
This project is led and funded in partnership with the EGFR Resisters.

While this list is not exclusive, additional areas of interest include: 

  • Methods for optimizing first-line EGFR TKI therapy
  • Novel combination treatment approaches
  • Identification of biomarkers to predict either sensitivity to specific therapies and/or timing of relapse on therapy
  • Effective treatment strategies for brain metastases and leptomeningeal disease

LCRF and MET Crusaders Research Grant on MET-Driven Lung Cancer
This project is led and funded in partnership with the MET Crusaders.

While not exclusive, additional areas of interest include work on new therapies for MET-dependent lung cancers such as:

  • Next-generation drugs or agents with novel mechanisms of action
  • Agents that improve the safety profile of existing therapies

LCRF and KRAS Kickers Research Grant on KRAS-Driven Lung Cancer
This project is led and funded in partnership with the KRAS Kickers.

While not exclusive, additional areas of interest include:

  • Evaluation of new therapeutic regimens (i.e. ADCs, targeted therapies, nanoparticles)
  • Translational studies that may lead to clinical trials
  • Assessment and impact of therapies on patients

LCRF – ALK Positive Research Grant

ALK Positive is partnering with the Lung Cancer Research Foundation (LCRF) to support ALK-positive non-small cell lung cancer research. Funded research projects are expected to have a direct impact on the outcomes of patients with advanced ALK-positive lung cancer, to ultimately transform care and improve outcomes for patients with ALK-positive NSCLC.

Projects may be either:

  • Translational studies that are aimed at impacting clinical decision-making within four years of notification of project award. For the purposes of this Request for Proposals (RFP), “impacting clinical decision-making” is defined as initiation of a clinical trial including ALK-positive cancer patients, or publication of research intended to improve ALK-positive cancer patient treatment outcomes.
  • Aspects of clinical trials

Suggested areas of investigation may include, but are not limited to, the following:

  • Understanding novel monotherapy and combination therapies. If there is an active Institutional Review Board (IRB) approval by the time of study commencement, addition of an ALK lung cancer arm to an existing/proposed clinical trial is acceptable.
  • Therapies in the post-lorlatinib or post-tyrosine kinase inhibitor (TKI) treatment space. 
  • Identifying biomarkers that predict drug efficacy and/or resistance, or timing and likelihood of relapse
  • Multiplex imaging or other high-throughput approaches to screen or characterize response or resistance to therapeutic regimens
  • Evaluation of real-world evidence (RWE) and real-world data (RWD) and how this can inform or change current practices
  • Understanding the clinical and genomic features of “short responses” to ALK TKIs and suggesting how to improve the treatment and monitoring for these situations. For the purposes of this RFP, short responses are defined as those where the progression-free survival is less than half the published median progression-free survival for a specific ALK TKI.
  • Understanding the clinical and genomic features of “long responses” to ALK TKIs and suggesting how to further improve treatment and monitoring in these cases. For the purposes of this RFP, long responses are defined as those where the progression-free survival is at least double the published median progression-free survival for a specific ALK TKI.
  • Understanding intratumoral heterogeneity, phenotypic shifts and the features and vulnerabilities of persister cells.
  • Characterizing the biology of early-stage ALK+ lung cancers and identifying biomarkers predictive of metastatic relapse.

Projects are to include at least one aim that is translational and has the potential to lead directly to improved outcomes for patients. Applicants will be asked to estimate the time frame for their research to result in a clinical trial.

These awards provide a maximum of $250,000 over two years. For complete details, eligibility criteria, and application instructions, please refer to the request for proposals.

Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. The deadline for Letters of Intent has been extended through June 1, 2022.


LCRF Research Grant on Early Detection and Pre-Neoplasia in Lung Cancer

LCRF has launched a funding mechanism to support research projects that facilitate or advance the understanding and characterization of pre-neoplasia or approaches for early detection of lung cancer. Work supported through this mechanism addresses important questions in non-small cell and small cell lung cancer.

This funding mechanism is focused on identifying, characterizing, and developing approaches and techniques that will allow early detection of lung cancer and gaining insight into pre-neoplastic processes in the lungs. The ultimate goal is to detect lung cancer at the earliest stages and subsequently increase survival and survivorship. While this list is not exclusive, general areas of interest include:  

  • Identification and characterization of new biomarkers for NSCLC and SCLC
  • Liquid biopsy assays and related techniques
  • Improvements in risk stratifying patients for screening
  • Development of predictive, diagnostic, or prognostic biomarkers
  • Genomic and histological approaches to improve early detection in tissue samples
  • Novel imaging modalities to identify and risk stratify pre-neoplastic lesions
  • Studies of pre-neoplasia and progression to lung neoplasia

These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. For full details, eligibility criteria, and application instructions, please refer to the request for proposals.

Applications will be submitted through a two-step process consisting of a Letter of Intent (LOI) and full proposal. Applicants whose LOI submission is reviewed favorably will be invited to complete a full proposal. Letters of Intent will be accepted through April 30, 2022.


LCRF Minority Career Development Award (CDA) in Lung Cancer

National Institutes of Health (NIH) funding is considered a prerequisite for establishing independence, academic promotion,  recognition as an expert, serving on grant review panels, and leadership roles. Minority applicants are less likely to receive grants, to have the R phases of K01 or K99 awards activated, need more submissions to obtain funding, and often will not resubmit proposals. As minority applicants must overcome systemic and structural barriers due to race, ethnicity, country of origin, socioeconomic status, and/or language, many leave academia which further exacerbates the lack of diversity in STEM and medical fields. To provide protected time and mentoring to these trainees, we are launching the LCRF Minority Career Development Award (CDA) for Lung Cancer for minority postdoctoral/clinical fellows and assistant professors within 10 years of completing their MD and/or PhD degrees to submit proposals.

We encourage applications on a wide variety of topics including but not limited to the following:

  • Lung cancer biology
  • Prevention and screening for early detection
  • Identification of new biomarkers
  • Development of more effective and less toxic therapies including but not limited to targeted and immune-therapies
  • Genetic and gene-environment interactions
  • Interactions and contributions of multiple factors (e.g. smoking, genetics, environment, societal factors) to disparities in lung cancer outcomes
  • Mechanisms of sensitivity and resistance to lung cancer therapies
  • Bioengineering approaches to understanding and/or treating lung cancer (i.e., theranostics, biomaterials, nanotechnology, controlled-drug release, and gene-therapy)
  • Supportive measures for people with lung cancer and their families

These awards provide a maximum of $150,000 in funding over a period of two years to early- and mid-career investigators. For complete details, eligibility criteria, and application instructions, please refer to the request for proposals.

The deadline for LCRF Minority Career Development Award (CDA) in Lung Cancer RFP applications has been extended through June 3, 2022.


Mailing List

To receive RFP announcements and other updates related to LCRF funding opportunities, you may subscribe to our mailing list using the form below. You may opt out of these communications at any time.

Name 
Email
Institution